#China #Shanghai #AbbVie #migraine therapies #Brise Pharmaceuticals

Brise Pharmaceuticals Partners with AbbVie to Advance Migraine Therapies

In a noteworthy move in the biopharmaceutical sector, Brise Pharmaceuticals Co., Ltd. has announced an exclusive licensing agreement with AbbVie, marking a significant step forward in the development of advanced migraine therapies. The agreement, reached in late 2024, creates an opportunity for both companies to leverage their strengths in addressing the challenges faced by patients suffering from debilitating migraine conditions.

Key Details of the Agreement

Under the terms of this collaboration, Brise will spearhead discovery efforts, harnessing its innovative platforms to propel research forward. Meanwhile, AbbVie will take charge of global development and commercialization. This strategic partnership enables Brise to focus on its unique research capabilities while benefiting from AbbVie’s extensive market experience and distribution network.

Guochun Li, the CEO of Brise Pharmaceuticals, expressed optimism about the collaboration: “This partnership is a crucial validation of our research in the migraine arena and reinforces our dedication to delivering potentially transformative medicines.” Li emphasized the importance of working alongside a heavyweight like AbbVie to maximize the potential of Brise’s innovative discovery engine.

The agreement is particularly impressive, with an aggregate potential transaction value that could reach $757 million, in addition to royalties attributable to future sales. This value encompasses various milestones related to development, commercialization, regulatory approval, and sales targets. Notably, Brise has already realized several immediate milestones since the agreement’s communication.

About Brise Pharmaceuticals

Founded in June 2021 in Shanghai, China, Brise Pharmaceuticals is on the cutting edge of pain management. The company is dedicated to transforming treatment paradigms for various types of pain, particularly focusing on migraines, nociceptive, neuropathic, and nociplastic pain. Through its multi-modality therapeutic approach, Brise aims to deliver differentiated and innovative treatments that significantly enhance patient outcomes and quality of life.

Brise’s pipeline includes BR005, an oral small-molecule medication originating in China, which is currently undergoing pivotal clinical trials for the acute treatment of adult migraines. In addition, the company is advancing several new therapeutic candidates, showcasing its commitment to pioneering innovative solutions in pain management.

The licensing agreement with AbbVie will not only further Brise’s mission but also reinforces its status in the marketplace as a formidable player dedicated to fighting migraine disorders through scientific innovation. By incorporating small molecules and targeted antibody therapeutics, Brise effectively modulates intricate pain pathways at the molecular level, promising a new horizon for migraine sufferers.

In conclusion, this collaboration between Brise Pharmaceuticals and AbbVie represents a pivotal moment in the realm of migraine therapy development. As both companies gear up to make meaningful advancements, patients can look forward to new treatment options that could change the way migraines are managed moving forward.

To learn more about Brise Pharmaceuticals’ pipeline and therapeutic innovations, please visit Brise Pharmaceuticals.